Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cells.

Ly BT, Chi HT, Yamagishi M, Kano Y, Hara Y, Nakano K, Sato Y, Watanabe T.

PLoS One. 2013 Jun 20;8(6):e66378. doi: 10.1371/journal.pone.0066378.

2.

The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.

Augustin E, Skwarska A, Weryszko A, Pelikant I, Sankowska E, Borowa-Mazgaj B.

Acta Pharmacol Sin. 2015 Mar;36(3):385-99. doi: 10.1038/aps.2014.142.

3.

CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.

Bertoli S, Boutzen H, David L, Larrue C, Vergez F, Fernandez-Vidal A, Yuan L, Hospital MA, Tamburini J, Demur C, Delabesse E, Saland E, Sarry JE, Galcera MO, Mansat-De Mas V, Didier C, Dozier C, Récher C, Manenti S.

Oncotarget. 2015 Nov 10;6(35):38061-78. doi: 10.18632/oncotarget.5706.

4.
5.

AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.

Barbarroja N, Torres LA, Rodriguez-Ariza A, Valverde-Estepa A, Lopez-Sanchez LM, Ruiz-Limon P, Perez-Sanchez C, Carretero RM, Velasco F, López-Pedrera C.

Exp Hematol. 2010 Aug;38(8):641-52. doi: 10.1016/j.exphem.2010.03.017.

PMID:
20380868
6.

Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.

Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff M.

Clin Cancer Res. 2014 May 1;20(9):2363-74. doi: 10.1158/1078-0432.CCR-13-2052.

7.

Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.

Larrue C, Saland E, Vergez F, Serhan N, Delabesse E, Mansat-De Mas V, Hospital MA, Tamburini J, Manenti S, Sarry JE, Récher C.

Mol Cancer Ther. 2015 Oct;14(10):2364-73. doi: 10.1158/1535-7163.MCT-15-0163.

8.

Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.

Stölzel F, Steudel C, Oelschlägel U, Mohr B, Koch S, Ehninger G, Thiede C.

Ann Hematol. 2010 Jul;89(7):653-62. doi: 10.1007/s00277-009-0889-1.

PMID:
20119833
9.

The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.

Grundy M, Seedhouse C, Shang S, Richardson J, Russell N, Pallis M.

Mol Cancer Ther. 2010 Mar;9(3):661-72. doi: 10.1158/1535-7163.MCT-09-1144.

10.

ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.

Shankar DB, Li J, Tapang P, Owen McCall J, Pease LJ, Dai Y, Wei RQ, Albert DH, Bouska JJ, Osterling DJ, Guo J, Marcotte PA, Johnson EF, Soni N, Hartandi K, Michaelides MR, Davidsen SK, Priceman SJ, Chang JC, Rhodes K, Shah N, Moore TB, Sakamoto KM, Glaser KB.

Blood. 2007 Apr 15;109(8):3400-8.

11.

MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.

Nishioka C, Ikezoe T, Yang J, Takeuchi S, Koeffler HP, Yokoyama A.

Leuk Res. 2008 Sep;32(9):1382-92. doi: 10.1016/j.leukres.2008.02.018.

PMID:
18394702
12.

Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.

Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G.

J Hematol Oncol. 2013 Mar 16;6:21. doi: 10.1186/1756-8722-6-21.

13.

Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.

Reikvam H, Hatfield KJ, Ersvaer E, Hovland R, Skavland J, Gjertsen BT, Petersen K, Bruserud O.

Br J Haematol. 2012 Feb;156(4):468-80. doi: 10.1111/j.1365-2141.2011.08960.x.

PMID:
22150087
14.

Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.

Hartman AD, Wilson-Weekes A, Suvannasankha A, Burgess GS, Phillips CA, Hincher KJ, Cripe LD, Boswell HS.

Exp Hematol. 2006 Oct;34(10):1360-76.

PMID:
16982329
15.

T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.

Alachkar H, Mutonga M, Malnassy G, Park JH, Fulton N, Woods A, Meng L, Kline J, Raca G, Odenike O, Takamatsu N, Miyamoto T, Matsuo Y, Stock W, Nakamura Y.

Oncotarget. 2015 Oct 20;6(32):33410-25. doi: 10.18632/oncotarget.5418.

16.

FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.

Nogami A, Oshikawa G, Okada K, Fukutake S, Umezawa Y, Nagao T, Kurosu T, Miura O.

Oncotarget. 2015 Apr 20;6(11):9189-205.

17.

Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.

Park IK, Mishra A, Chandler J, Whitman SP, Marcucci G, Caligiuri MA.

Blood. 2013 Mar 14;121(11):2064-73. doi: 10.1182/blood-2012-07-444018.

18.

Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.

Okamoto M, Hayakawa F, Miyata Y, Watamoto K, Emi N, Abe A, Kiyoi H, Towatari M, Naoe T.

Leukemia. 2007 Mar;21(3):403-10.

PMID:
17230226
19.

Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.

Wu H, Hu C, Wang A, Weisberg EL, Wang W, Chen C, Zhao Z, Yu K, Liu J, Wu J, Nonami A, Wang L, Wang B, Stone RM, Liu S, Griffin JD, Liu J, Liu Q.

Leukemia. 2016 Mar;30(3):754-7. doi: 10.1038/leu.2015.175. No abstract available.

20.

FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.

Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, Iino T, Rocnik JL, Kikushige Y, Mori Y, Shima T, Iwasaki H, Takenaka K, Nagafuji K, Mizuno S, Niiro H, Gilliland GD, Akashi K.

Blood. 2009 Dec 3;114(24):5034-43. doi: 10.1182/blood-2008-12-196055.

Items per page

Supplemental Content

Support Center